Phoenix Nest Inc.
Brooklyn, NY · Biotech · Private
Recombinant human alpha-N-acetylglucosamine-6-sulfatase (rhGNS) enzyme replacement therapy delivered via intracerebroventricular infusion for MPS IIID
- Grants
- $9.7M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 0 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development and in vitro validation of therapy for mucopolysaccharidosis III | $1,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineering stem cells to make mucopolysaccharidosis IIIB | $224,469 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineering stem cells to make mucopolysaccharidosis IIIB | $224,469 | |
| Federal grant | Department of Health and Human Services · Phase II · Development and validation of therapy for mucopolysaccharidosis III | $717,207 | |
| Federal grant | Department of Health and Human Services · Phase II · Development and validation of therapy for mucopolysaccharidosis III | $777,801 | |
| Federal grant | Department of Health and Human Services · Phase I · Structure-based optimization of a novel pharmacological chaperone therapy for MPSIIIC | $224,873 | |
| Federal grant | Department of Health and Human Services · Phase II · Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients | $2,621,593 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of gene replacement therapy for Sanfilippo Syndrome Type C | $1,495,610 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Gene Replacement Therapy for Sanfilippo Syndrome Type C | $1,494,895 | |
| Federal grant | Department of Health and Human Services · Phase II · Identification of Potential Biomarkers and Clinical Tools for use in Mucopolysaccharidosis IIIC Patients. | $881,675 | |
| Federal grant | Department of Health and Human Services · Phase II · Identification of Potential Biomarkers and Clinical Tools for use in Mucopolysaccharidosis IIIC Patients. | $1,062,505 |
Federal grant · SBIR/STTRPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1703 | BIOSPUTNIK LLC | — | — |
| 1704 | ONEVAX, LLC | — | — |
| 1705 | Prokaryotics, Inc. | — | — |
| 1706 | Phoenix Nest Inc. | — | — |
| 1707 | Remedy Labs, Inc. | — | $500K |
| 1708 | STOECKER MD, WILLIAM V | — | — |
| 1709 | MTI BIOTECH, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
Phoenix Nest Awarded Prestigious Small Business Innovation Research (SBIR) Grant of $2,984,658PRNewswire
Patents
- Nootropic Peptides For Treating Lysosomal Storage Diseasesapplication
- Enzyme Replacement Therapy For Mucopolysaccharidosis Iiidapplication
- Nootropic Peptides For Treating Lysosomal Storage Diseasesapplication
- Nootropic Peptides For Treating Lysosomal Storage Diseasesapplication
- Enzyme Replacement Therapy For Mucopolysaccharidosis Iiidapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.